The impact of overweight on renal toxicity in patients treated with dexamethasone, high-dose cytarabine, and cisplatin.


Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 09 07 2019
accepted: 07 11 2019
revised: 03 11 2019
pubmed: 16 11 2019
medline: 28 8 2020
entrez: 16 11 2019
Statut: ppublish

Résumé

The combination of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) is used as salvage chemotherapy for relapsed or refractory lymphoma. It includes the administration of cisplatin in a single dose of 100 mg/m

Identifiants

pubmed: 31728828
doi: 10.1007/s12185-019-02779-8
pii: 10.1007/s12185-019-02779-8
doi:

Substances chimiques

Antineoplastic Agents 0
Cytarabine 04079A1RDZ
Dexamethasone 7S5I7G3JQL
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

396-400

Références

Int J Hematol. 2019 Aug;110(2):131-146
pubmed: 31177376
BMC Cancer. 2016 Apr 11;16:267
pubmed: 27067641
Leuk Res. 2017 Jul;58:98-101
pubmed: 28521176
J Clin Oncol. 2018 Mar 1;36(7):682-688
pubmed: 29320311
J Clin Oncol. 2016 Aug 20;34(24):2881-7
pubmed: 27400948
PLoS One. 2014 Jul 14;9(7):e101902
pubmed: 25020203
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Haematologica. 2008 Dec;93(12):1829-36
pubmed: 18945747
Biol Pharm Bull. 2016;39(12):2009-2014
pubmed: 27904042
Blood. 1991 Apr 1;77(7):1587-92
pubmed: 2009374
Ann Hematol. 2017 Jun;96(6):943-950
pubmed: 28374163
Br J Cancer. 2003 Apr 22;88(8):1199-206
pubmed: 12698184
JAMA Oncol. 2015 Sep;1(6):737-45
pubmed: 26181758
J Am Soc Nephrol. 2003 Jan;14(1):1-10
pubmed: 12506132
J Clin Oncol. 2014 Nov 1;32(31):3490-6
pubmed: 25267740
J Clin Oncol. 2010 Sep 20;28(27):4184-90
pubmed: 20660832
Ann Hematol. 2016 Sep;95(9):1513-9
pubmed: 27365141

Auteurs

Kento Umino (K)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Kaoru Hatano (K)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Shin-Ichi Ochi (SI)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Harunobu Genda (H)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Takashi Ikeda (T)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Shin-Ichiro Kawaguchi (SI)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Yumiko Toda (Y)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Shoko Ito (S)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Takashi Nagayama (T)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Kiyomi Mashima (K)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Daisuke Minakata (D)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Hirofumi Nakano (H)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Ryoko Yamasaki (R)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Kaoru Morita (K)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Chihiro Yamamoto (C)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Masahiro Ashizawa (M)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Kazuya Sato (K)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Iekuni Oh (I)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Shin-Ichiro Fujiwara (SI)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Ken Ohmine (K)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Kazuo Muroi (K)

Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Yoshinobu Kanda (Y)

Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. ycanda-tky@umin.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH